Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Dilek Yazman"'
Autor:
Ali Temelci, Hasan Güney Yılmaz, Gürkan Ünsal, Lokman Onur Uyanik, Dilek Yazman, Aysa Ayali, Giuseppe Minervini
Publikováno v:
Biomimetics, Vol 8, Iss 1, p 25 (2023)
Background and Objectives: Beta-thalassemia (BT) has a high prevalence in Mediterranean, Southeast Asian, and African countries. Studies stated that thalassemia is an endemic disease that causes significant health problems in Cyprus. This study aimed
Externí odkaz:
https://doaj.org/article/fec20323de894facab5fa6210c2042b0
Autor:
Usama El-Safy, M. Akif Yesilipek, Yousryeia Abdel Rahman, Zakaria Al Hawsawi, Youssef Al-Tonbary, Ghazi Al Damanhouri, Shebl Said Shebl, Fernando Tricta, Yurdanur Kilinç, Mostafa A.S Salama, Zeynep Karakas, Mohamad H. Qari, Mohamed M. Badr, M Elalfy, Anne Stilman, Dilek Yazman, Noemi Toiber Temin, Yasser Wali
Publikováno v:
Pediatric Blood & Cancer. 61:879-884
Background A risk associated with the iron chelator deferiprone is the development of neutropenia or agranulocytosis. Accordingly, the product label recommends weekly blood monitoring and immediate interruption of treatment upon detection of an absol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0551706f0054578fe85dc27e7f3194b
https://doi.org/10.1002/pbc.24920
https://doi.org/10.1002/pbc.24920
Autor:
Anita Kolnagou, Eleni Eracleous, Dilek Yazman, George J. Kontoghiorghes, Charalambos Economides
Publikováno v:
Hemoglobin. 33:312-322
Excess cardiac iron deposition leads to congestive cardiac failure and accounts for more than 70% of deaths in thalassemia major patients. In three separate studies involving 145 thalassemia patients, serum ferritin and magnetic resonance imaging (MR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::989ab99640d5ad9e6a1297297e12ae59
https://doi.org/10.3109/03630260903213231
https://doi.org/10.3109/03630260903213231
Autor:
Mohssen, Elalfy, Yasser A, Wali, Mohamad, Qari, Ghazi, Al Damanhouri, Youssef, Al-Tonbary, Dilek, Yazman, Zakaria, Al Hawsawi, Zeynep, Karakas, Yurdanur, Kilinc, M Akif, Yesilipek, Mohamed, Badr, Usama, Elsafy, Mostafa, Salama, Yousryeia, Abdel Rahman, Shebl, Shebl, Anne, Stilman, Noemi, Toiber Temin, Fernando, Tricta
Publikováno v:
Pediatric bloodcancer. 61(5)
A risk associated with the iron chelator deferiprone is the development of neutropenia or agranulocytosis. Accordingly, the product label recommends weekly blood monitoring and immediate interruption of treatment upon detection of an absolute neutrop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0292bebcd58ec8df89ba355bdf7621c4
https://pubmed.ncbi.nlm.nih.gov/24376176
https://pubmed.ncbi.nlm.nih.gov/24376176
Autor:
Zeynep Karakas, Yasser Wali, Shebl Said Shebl, M. Akif Yesilipek, Mohamad H. Qari, Fernando Tricta, Ghazi Abdullah Al Damnhouri, Mostafa A.S Salama, Dilek Yazman, Yurdanur Kilinç, M. A. Badr, Yousryeia Abdel Rahman, Zakaria Al Hawsawi, Youssef Al-Tonbary, Mohsen Saleh Elalfy, Usama El-Safy
Publikováno v:
Blood. 120:996-996
Abstract 996 The incidence of agranulocytosis during deferiprone (Ferriprox®) use has been reported in clinical trials where patients' neutrophil counts were generally monitored weekly and deferiprone was discontinued at the first sign of neutropeni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fe0d99029f7c9fd115ea349564c620c
https://doi.org/10.1182/blood.v120.21.996.996
https://doi.org/10.1182/blood.v120.21.996.996